Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays

Qiagen N.V. (NYSE:QGEN) ranks among the best CRISPR stocks to buy. Qiagen N.V. (NYSE:QGEN) and Gencurix announced a collaboration on June 18 to provide oncology assays for Qiagen’s QIAcuityDx digital PCR platform.

Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays

The collaboration will focus on developing multiplex cancer assays for use in liquid and tissue biopsies. As the authorized manufacturer, Gencurix will create a number of cancer tests while striving to obtain IVD regulatory clearances. Following approval, Qiagen’s global commercial infrastructure will be used for marketing the assays.

The collaboration makes use of QIAGEN’s QIAcuityDx platform, a member of the QIAcuity family of digital PCR technologies, which by the end of 2024 had achieved over 2,700 total placements.

Furthermore, Qiagen N.V. (NYSE:QGEN) recently concluded the acquisition of Genoox for $70 million, with possible extra milestone payments, in order to improve its capacity for genetic data analysis. Qiagen’s Digital Insights suite now incorporates Genoox’s Franklin platform.

A global leader in Sample to Insight solutions, Qiagen N.V. (NYSE:QGEN) offers tools for extracting and analyzing proteins, RNA, and DNA from a variety of samples.

While we acknowledge the potential of QGEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.